Search Results
Your search for texas a matches 2595 pages
Showing 1651 - 1700ASCO Launches JCO Clinical Cancer Informatics
JCO Clinical Care Informatics (JCO CCI) will be the first ASCO journal devoted to applications of biomedical informatics to cancer care. Debra Patt, MD, MPH, MBA, the Editor-in-Chief of JCO CCI, understands how important biomedical informatics research is to the oncology field. Dr. Patt coauthored ...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time member and volunteer, has been elected to serve as President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to the ASCO...
Moffitt Cancer Center Names Robert Wenham, MD, MS, FACOG, FACS, Gynecologic Oncology Program Chair
Moffitt Cancer Center has appointed Robert Wenham, MD, MS, FACOG, FACS, as the new Gynecologic Oncology Program Chair. Dr. Wenham has served as the Interim Chair over the past several months. He was recruited to Moffitt in 2004, after completing his fellowship in gynecologic oncology at the Duke...
CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
Osimertinib Significantly Improves Survival for Patients With Non–Small Cell Lung Cancer
For patients with epidermal growth factor receptor (EGFR) T790M–positive non–small cell lung cancer (NSCLC), osimertinib (Tagrisso) demonstrated clinically superior efficacy over pemetrexed (Alimta) plus a platinum agent, with a 70% reduction in the risk of disease progression, according to the...
‘Collateral Lethality’ May Offer New Therapeutic Approach for Cancers of the Pancreas, Stomach, and Colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers. Scientists at The University of Texas MD ...
Most Federal Exchange Plans Under Affordable Care Act Do Not Contain NCI-Designated Cancer Center
In a study reported in the Journal of Clinical Oncology, Kehl et al found that most federal exchange networks under the Affordable Care Act contain a Commission on Cancer–accredited hospital, but less than half contain a National Cancer Institute (NCI)-designated cancer center. Study Details ...
NCI-Designated Cancer Centers Issue Statement in Support of New CDC Recommendations on HPV Vaccination
The 69 National Cancer Institute (NCI)-designated cancer centers have issued a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC) to improve national vaccination rates for human papillomavirus (HPV). According to the CDC,...
Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
Expert Point of View: Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The landscape has changed. Now we treat postmenopausal hormone receptor–positive, HER2-negative metastatic...
American Cancer Society Welcomes Three New Members and Newly Elected Officers to Board of Directors
The American Cancer Society announced the election of three new members—Amit Kumar, PhD, Joseph M. Naylor, and William D. Novelli—to the 2017 American Cancer Society Board of Directors. In addition, the new key officer leadership positions were announced, which include Arnold M. Baskies,...
A Lesson From David
The following essay by Jeremy K. Hon, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. As physicians, ...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html 2017 Highlights of ASH in North...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
Richard Gorlick, MD, Joins MD Anderson to Lead Pediatrics
Richard Gorlick, MD, an expert in pediatric oncology and hematology, has joined The University of Texas MD Anderson Children’s Cancer Hospital as the Division Head and Department Chair of Pediatrics. A pediatric cancer survivor himself, Dr. Gorlick committed his life’s work to helping young...
SABCS 2016: Scalp-Cooling Device Safe and Effective in Reducing Chemotherapy-Induced Alopecia in Women With Breast Cancer
Although adjuvant chemotherapy decreases the risk of breast cancer recurrence, it is associated with distressing side effects, including hair loss. A prospective randomized trial evaluating the safety and efficacy of the Orbis Paxman Hair Loss Prevention System (OPHLPS), a scalp-cooling device that ...
Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer
In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...
Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
The Leukemia & Lymphoma Society Invests $40.3 Million in New Research to Find Cures for Hematologic Malignancies
The Leukemia & Lymphoma Society (LLS) has announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute; Weill Cornell Medicine; Memorial...
AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow
Dong Moon Shin, MD, the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research at Winship Cancer Institute of Emory University, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Shin is Professor of Hematology and Medical Oncology,...
Mylin A. Torres, MD, to Hold Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute
Mylin A. Torres, MD, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University (Winship), was selected to hold the Louisa and Rand Glenn Family Chair in Breast Cancer Research. The endowed position was created by the Wilbur and Hilda Glenn Family Foundation to...
A Decade of Impact: Conquer Cancer Foundation/Kidney Cancer Association Young Investigator Awards
The Kidney Cancer Association has supported 12 kidney cancer research projects through the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) program over the past decade. Early seed funding from the Kidney Cancer Association is advancing research, improving the lives of ...
University of Hawaii Cancer Center Receives $3 Million R01 NCI Grant for Bladder Cancer Research
Charles Rosser, MD, MBA, FACS, Professor and Director of the Clinical Trials Office and Director of the Clinical and Translational Research Program at the University of Hawaii Cancer Center, received a 5-year National Cancer Institute (NCI) R01 grant worth more than $3 million. The grant is for...
What’s New in Antiemesis Therapy
The optimal use of new antiemetics was the subject of a presentation at the 14th Annual School of Breast Oncology, Emory University, Atlanta, by Frankie Ann Holmes, MD, Associate Director of Breast Oncology Research at Texas Oncology, Houston. “The science of nausea and vomiting is so compelling,...
Fergus J. Couch, PhD, and Max S. Wicha, MD, Recognized for Significant Contributions to Breast Cancer Research at 2016 SABCS
The American Association for Cancer Research (AACR) honored two renowned researchers for their work in breast cancer at the 2016 San Antonio Breast Cancer Symposium (SABCS), held December 6–10 in San Antonio, Texas. Fergus J. Couch, PhD, of the Mayo Clinic, will receive the 9th Annual AACR...
Disparities of Care: Navigation System Helps Connect Underserved Populations to Cancer Services
Although we’ve seen substantial progress in cancer treatment, screening, diagnosis, and prevention over the past decades, certain underserved populations have not reaped the benefits of many of these advances. Turning research into actionable programs in this area was highlighted by a presentation ...
Noteworthy Antitumor Activity Seen in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes encode receptor tyrosine kinases, and when they are mutated, cell signaling malfunctions, leading to...
MD Anderson Cancer Center Marks 75 Years of Research to End Cancer
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...
Activating NOTCH1 Mutations Identify Poor-Prognostic Subgroup With Adenoid Cystic Carcinoma
In a study reported in the Journal of Clinical Oncology, Ferrarotto et al found that the presence of activating NOTCH1 mutations defined a subgroup of patients with adenoid cystic carcinomas with an aggressive phenotype. Frequency of Mutations The study included genotyping of 102 adenoid cystic...
ASH 2016: Study Shows Patients Traditionally Ineligible for Studies May Benefit From Trial Participation
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses. A novel study at The University of Texas MD Anderson Cancer Center revealed some patients with acute...
ASH 2016: Biomarker May Predict Which Patients Previously Treated for Cancer Will Develop Highly Fatal Form of Leukemia
Patients successfully treated for breast, colon, and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms. A study conducted by...
EORTC-NCI-AACR 2016: ‘Remarkable Antitumor Activity’ in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes provide instructions for making proteins that are part of a family of proteins called receptor...
FDA Grants Full Approval and Label Update for Ponatinib in CML and ALL
The U.S. Food and Drug Administration (FDA) has granted ponatinib (Iclusig) full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) for whom no ...
Nivolumab in Recurrent Advanced Urothelial Carcinoma
In the phase I/II CheckMate 032 trial reported in The Lancet Oncology, Padmanee Sharma, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that nivolumab (Opdivo) was active in locally advanced or metastatic urothelial carcinoma progressing after platinum-based therapy....
ASH Honors J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD, With the 2016 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
ASH Reports Highest-Scoring Abstracts by Early-Career Researchers for Annual Meeting
The American Society of Hematology (ASH) recently announced that the following trainees received the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow for the 58th ASH Annual Meeting, December...
CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma
As reported by Angela N. Bartley, MD, of St Joseph Mercy Hospital, Ann Arbor, and colleagues in the Journal of Clinical Oncology, the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and ASCO have released a guideline on HER2 testing and clinical...
Activation of WNT5A May Drive Glioblastoma Stem Cell Differentiation and Invasive Growth
Glioblastoma multiforme remains the most common and highly lethal brain cancer, known for its tendency to recur. Researchers at The University of Texas MD Anderson Cancer Center have identified a pathway by which cancer cells aggressively spread and grow in the brain, opening up new possibilities...
The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
SITC 2016: Immune Checkpoint Inhibitors Shrink Tumors in Some Patients With Metastatic Bladder Cancer
Combination immunotherapy is producing response rates ranging from 26% to 38% among patients with metastatic bladder cancer in the early stages of a three-arm clinical trial presented at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. “Until...
Impact of Neoadjuvant Therapy on Survival in Resectable Pancreatic Cancer
In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Patricio M. Polanco, MD, of the Division of Surgical...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review ...
ASCO’s Quality Training Program Shifts to a Regional Setting; Applications Now Open for 2017
On October 17, applications opened for ASCO’s 2017 Quality Training Program. For 2017, the program, which began 3 years ago, is shifting its model of in-person sessions at ASCO headquarters in Alexandria, Virginia, to regional settings. The program is designed to train oncology health-care...
ASCO Announces Candidates for 2017 Election
Twelve distinguished ASCO members have been selected by the Nominating Committee as candidates for open leadership positions within the Society, including the office of President-Elect, three seats on the Board of Directors, and two seats on the Nominating Committee. Biographical information and...
Improved Outcome Reported With Local Consolidative Therapy in Oligometastatic NSCLC Without Progression After First-Line Systemic Therapy
In a phase II trial reported in The Lancet Oncology, Gomez et al found that local consolidative therapy (with or without maintenance therapy) improved progression-free survival in patients with stage IV non–small cell lung cancer (NSCLC) who had up to three metastatic disease lesions and no...
Gut Microbes Linked to Immunotherapy Response in Patients With Melanoma
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they have greater diversity in their gut bacteria, according to new research presented by Wargo et al at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool, United Kingdom....
Personalized Risk Assessment Tool for Lung Cancer in Never, Light, and Heavy Smokers
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light, and heavy smokers using a large Taiwanese prospective cohort study. By incorporating risk factor—in addition to...
Venetoclax Monotherapy Safe and Clinically Active in Acute Myelogenous Leukemia
A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were...
